Breaking News Instant updates and real-time market news.

HON

Honeywell

$106.91

-0.03 (-0.03%)

, UTX

United Technologies

$100.72

0.14 (0.14%)

10:25
10/10/16
10/10
10:25
10/10/16
10:25

On The Fly: Top five analyst downgrades

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Honeywell (HON) downgraded to Buy from Conviction Buy at Goldman with analyst Christopher Glynn lowering his Q3 Earnings Per Share expectations for Honeywell after the company cut its earnings and revenue outlook and trimmed his price target to $122 from $128. 2. United Technologies (UTX) downgraded to Neutral from Buy at Citi with analyst Jason Gursky saying he sees three issues limiting share upside over the next twelve-plus months. 3. PNC Financial (PNC) was downgraded to Neutral from Buy at Nomura while the firm downgraded Fifth Third (FITB) to Reduce from Neutral. 4. Myriad Genetics (MYGN) downgraded to Sell from Neutral at Ladenburg with analyst Kevin DeGeeter citing a "significant and unexpected deterioration" in outlook for the company's companion diagnostic franchise. 5. HSN, Inc. (HSNI) downgraded to Hold from Buy at Craig-Hallum with analyst Alex Fuhrman saying his channel checks indicate continued weakness in the third quarter, with particular weakness in jewelry and consumer electronics. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

HON

Honeywell

$106.91

-0.03 (-0.03%)

UTX

United Technologies

$100.72

0.14 (0.14%)

PNC

PNC Financial

$91.67

0.25 (0.27%)

FITB

Fifth Third

$20.69

-0.05 (-0.24%)

MYGN

Myriad Genetics

$21.35

0.165 (0.78%)

HSNI

HSN, Inc.

$39.74

0.37 (0.94%)

  • 10

    Oct

  • 12

    Oct

  • 14

    Oct

  • 20

    Oct

  • 21

    Oct

  • 25

    Oct

  • 13

    Jan

HON Honeywell
$106.91

-0.03 (-0.03%)

10/10/16
GSCO
10/10/16
DOWNGRADE
Target $122
GSCO
Buy
Honeywell downgraded to Buy from Conviction Buy at Goldman
Goldman analyst Joe Ritchie removed Honeywell form the Conviction Buy List following the Q3 preannouncement and initial 2017 outlook. The analyst has reduced conviction in Honeywell's execution after 3 quarters of EBIT misses and said Honeywell has become a "show me" story and lowered his price target to $122 from $131 on shares. Ritchie continues to rate Honeywell a Buy saying shares are cheap and fundamentals are above average but consistency in execution/communication needs to return to prior levels to help narrow the valuation gap.
10/07/16
JPMS
10/07/16
NO CHANGE
JPMS
Overweight
Honeywell selloff on guidance a buying opportunity, says JPMorgan
JPMorgan analyst C. Stephen Tusa recommends using the selloff in shares of Honeywell following the company's Q3 guidance cut as a buying opportunity. The analyst puts himself in the "not that bad in the grand scheme" camp and notes Honeywell has $25B in balance sheet capacity. Tusa has an Overweight rating on the shares.
10/07/16
BERN
10/07/16
NO CHANGE
BERN
Honeywell still has positive attributes, says Bernstein
After Honeywell lowered its guidance and announced restructuring plans, Bernstein analyst Steven Winoker said that macro conditions and margins/restructuring led to the disappointing news. However, the analyst says that there are still multiple reasons to be upbeat on the stock, including his belief that the company's EPS growth will exceed 8% next year, and what he sees as the company's high margins and large cash reserves. The analyst keeps a $135 price target and Outperform rating on the stock.
10/10/16
OPCO
10/10/16
NO CHANGE
Target $122
OPCO
Outperform
Honeywell price target lowered to $122 from $128 at Oppenheimer
Oppenheimer analyst Christopher Glynn lowered his Q3 EPS expectations for Honeywell after the company cut its earnings and revenue outlook and trimmed his price target to $122 from $128. While he expects shares to be placed in the "penalty box" for some months, he maintains an Outperform rating on the stock, assuming the multiple on the stock can return to the level of Oct. 6 as investor sentiment normalizes.
UTX United Technologies
$100.72

0.14 (0.14%)

05/03/16
RBCM
05/03/16
DOWNGRADE
RBCM
Sector Perform
United Technologies downgraded at RBC Capital
As noted earlier, RBC Capital downgraded United Technologies (UTX) to Sector Perform from Outperform. The firm says that Honeywell's (HON) actions indicate that it's no longer interested in buying United Technologies, while the latter company hasn't looked to increase the amount of cash it returns to shareholders. Additionally, RBC Capital is concerned about problems with United Technologies' geared turbo fan engine. Target to $108 from $109.
10/06/16
BARD
10/06/16
INITIATION
Target $110
BARD
Neutral
United Technologies initiated with a Neutral at Baird
Baird analyst Peter.Arment initiated United Technologies with a Neutral and a $110 price target.
10/10/16
SBSH
10/10/16
DOWNGRADE
Target $109
SBSH
Neutral
United Technologies downgraded to Neutral from Buy at Citi
Citi analyst Jason Gursky downgraded United Technologies to Neutral saying he sees three issues limiting share upside over the next twelve-plus months. Gursky believes 2017 consensus estimates are too high and that management is likely to reduce its 2020 targets at March's annual investor day. Further, he highlights manufacturing issues on the new GTF engine. The analyst cut his price target for the shares to $109 from $115.
05/03/16
05/03/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. ACADIA (ACAD) downgraded to Market Perform at Leerink by analyst Paul Matteis, who said his 2016-2018 revenue estimates are below consensus. The analyst said that consensus estimates for the pimavanserin launch "may overlook a collection of minor headwinds." He admits that ACADIA could be attractive to multiple potential buyers, including Biogen (BIIB) and Amgen (AMGN).2. Sarepta (SRPT) downgraded to Underperform at Leerink with analyst Joseph Schwartz believing the FDA's interpretation of empirical data for eteplirsen will be consistent with the recent negative panel, which was critical despite powerful human testimonies. 3. Community Health (CYH) downgraded to Underperform at BofA/Merrill by analyst Kevin Fischbeck, who said Q1 was disappointing. The analyst does not see volumes accelerating and is skeptical the company can turn around HMA assets in the near-term enough to hit margin targets. 4. United Technologies (UTX) downgraded to Sector Perform at RBC Capital because the firm says that Honeywell's (HON) actions indicate that it's no longer interested in buying United Technologies. The firm also said that Honeywell hasn't looked to increase the amount of cash it returns to shareholders. 5. On Deck Capital (ONDK) downgraded to Underperform at Sterne Agee CRT, to Hold at Canaccord and Needham, and to Neutral at BTIG following its weaker than expected Q1 results and guidance cut. Canaccord analyst Michael Graham said tepid originations growth raises concerns regarding borrowing demand and sees increased uncertainties cropping up. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
PNC PNC Financial
$91.67

0.25 (0.27%)

10/10/16
NOMU
10/10/16
DOWNGRADE
NOMU
Neutral
PNC Financial downgraded to Neutral from Buy at Nomura
Nomura analyst Bill Carcache downgraded PNC Financial to Neutral due to valuation and maintained his $89 price target on shares.
10/06/16
10/06/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. AutoNation (AN) upgraded to Neutral from Sell at Goldman with analyst David Tamberrino saying valuation has bottomed and could be flat to slightly up in the near-term as SAAR bounces around the low-to-mid 17M range. 2. Trina Solar (TSL), Yingli Green Energy (YGE), and JA Solar (JASO) were upgraded to Buy from Sell at Axiom while the firm upgraded SolarCity (SCTY) to Hold from Sell. 3. PNC Financial (PNC) upgraded to Market Perform from Underperform at Raymond James with analyst David Long saying negative earnings revisions over the past two years have likely hit an inflection point. 4. Big 5 Sporting (BGFV) upgraded to Buy from Hold at Deutsche Bank with analyst Mike Baker citing accelerating sales trends and higher earnings power from profitability improvements. 5. Booz Allen (BAH) upgraded to Outperform from Market Perform at Raymond James with analyst Brian Gesuale saying the recent selloff creates an attractive entry point. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/06/16
RAJA
10/06/16
UPGRADE
RAJA
Market Perform
PNC Financial upgraded to Market Perform from Underperform at Raymond James
Raymond James analyst David Long upgraded PNC Financial ahead of the Q3 report saying negative earnings revisions over the past two years have likely hit an inflection point.
09/19/16
BMOC
09/19/16
UPGRADE
BMOC
Outperform
PNC Financial upgraded on imrpoved outlook at BMO Capital
As noted earlier, BMO Capital upgraded PNC to Outperform from Market Perform. Analyst Lana Chan says she thinks that the company's results can beat expectations going forward, driven by fee income, tight expense management, and acceleration in loan growth over the next few years. She says that the stock's valuation is "compelling." Target to $101 from $94.
FITB Fifth Third
$20.69

-0.05 (-0.24%)

10/07/16
10/07/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Zillow (ZG, Z) initiated with a Buy at Needham. 2. AMD (AMD) initiated with an Equal Weight at Barclays. 3. Aflac (AFL) was initiated with an Underperform at Credit Suisse while the firm also initiated Prudential (PRU) and Assurant (AIZ) with a Neutral. 4. Fifth Third (FITB) initiated with a Neutral at Wedbush. 5. GW Pharmaceuticals (GWPH) initiated with a Buy at Goldman. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/07/16
10/07/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Tyson Foods (TSN) downgraded to Sell from Hold at Pivotal Research with analyst Timothy Ramey citing the broiler price-fixing alleged in the class action complaint filed on September 2. 2. SolarEdge (SEDG) was downgraded to Sell from Neutral at Goldman while the firm also downgraded First Solar (FSLR) to Neutral from Buy. 3. CIT Group (CIT) downgraded to Hold from Buy at Stifel with analyst Christopher Brendler saying investors should sell into the rally that will result from the "impressive" price that the company received for its aircraft business and the approval of its capital plan by the Fed. 4. Fifth Third (FITB) downgraded to Hold from Buy at Jefferies with analyst Ken Usdin saying the shares are reasonably valued following the recent rally. 5. Blackhawk (HAWK) downgraded to Neutral from Buy at BofA/Merrill with analyst David Chu saying the firm's channel checks indicate that conversions to EMV, the new standard for chip-based debit/credit card transactions, are taking longer than expected, which he believes could impact Blackhawk's 2016 guidance and expectations for 2017. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/10/16
NOMU
10/10/16
DOWNGRADE
Target $16
NOMU
Reduce
Fifth Third downgraded to Reduce from Neutral at Nomura
Nomura analyst Bill Carcache downgraded Fifth Third to Reduce and maintained its $16 price target. The analyst expects shares to underperform due to a combination of disappointing loan growth, securities reinvestment headwinds, and negative earnings revisions.
10/07/16
JEFF
10/07/16
DOWNGRADE
Target $22
JEFF
Hold
Fifth Third downgraded to Hold from Buy at Jefferies
Jefferies analyst Ken Usdin downgraded Fifth Third Bancorp to Hold saying the shares are reasonably valued following the recent rally. The analyst raised his price target for the stock to $22 from $19.50.
MYGN Myriad Genetics
$21.35

0.165 (0.78%)

08/11/16
SPHN
08/11/16
NO CHANGE
Target $30
SPHN
Overweight
Myriad Genetics price target lowered to $30 from $47 at Stephens
Stephens analyst Drew Jones lowered his price target for Myriad Genetics to $30 from $47 after the company missed Q4 expectations slightly and issued "disappointing" 2017 guide. The analyst sees hereditary cancer as the "primary culprit," with sales turnover blamed for volume weakness. Further, Jones believes the lack of visibility into this weakness has created an overhang that will not be solved with "one decent quarter." He reiterates an Overweight rating on the shares.
10/10/16
LTCO
10/10/16
DOWNGRADE
Target $16
LTCO
Sell
Myriad Genetics downgraded to Sell from Neutral at Ladenburg
Ladenburg Thalmann analyst Kevin DeGeeter downgraded Myriad Genetics (MYGN) to Sell citing a "significant and unexpected deterioration" in outlook for the company's companion diagnostic franchise. The analyst expects a lower growth outlook to drive "significant P/E multiple compression." Tesaro (TSRO) presented data this weekend that suggested its PARP inhibitor niraparib was active in a maintenance setting for recurrent ovarian cancer in patients with either positive or negative HRD scores. The analyst had expected the drug to benefit only HRD positive patients. As such, the use of niraparib will not require HRD testing, DeGeeter tells investors in a research note. The analyst has a $16 price target for the shares.
10/10/16
PIPR
10/10/16
NO CHANGE
PIPR
Neutral
TESARO data suggest Myriad test not necessary, says Piper Jaffray
Piper Jaffray analyst William Quirk points out that data over the weekend from TESARO (TSRO), Myriad Genetics' (MYGN) companion diagnostic partner, suggest niraparib works in all-comers, making Myriad's test not necessary. Myriad shares may be down physiologically, Quirk tells investors in a research note partially titled "When A Partnership Produces Mixed Results." The analyst, however, believes niraparib is not clinically significant in HRD negative patients and that Myriad's test will be included on the drug label. He keeps a Neutral rating on shares of Myriad. Ladenburg Thalmann this morning downgraded the stock to Neutral.
08/29/16
BOFA
08/29/16
NO CHANGE
BOFA
Myriad Genetics loses BCBS of Nevada contract to LabCorp, says BofA/Merrill
Analysts at BofA Merrill Lynch noted that Myriad Genetics (MYGN) has lost an in-network contract with Blue Cross Blue Shield of Nevada to LabCorp (LH) and the firm expects Myriad shares to trade down following the news. The firm sees the potential for a continuation of this trend across other BCBS systems in other states.
HSNI HSN, Inc.
$39.74

0.37 (0.94%)

10/10/16
CHLM
10/10/16
DOWNGRADE
Target $42
CHLM
Hold
HSN, Inc. downgraded to Hold from Buy at Craig-Hallum
Craig-Hallum analyst Alex Fuhrman downgraded HSN, Inc to Hold and lowered its price target to $42 from $62. Fuhrman's channel checks indicate continued weakness in Q3, with particular weakness in jewelry and consumer electronics. He now estimates net sales to decline 3% year-over-year in Q3 versus his prior estimate for a 1% decline and doesn't expect results to start improving until 2017.
09/20/16
BOFA
09/20/16
INITIATION
Target $33
BOFA
Underperform
HSN, Inc. initiated with an Underperform at BofA/Merrill
BofA/Merrill analyst Heather Balsky initiated HSN, Inc with an Underperform and a $33 price target. The analyst believes the company's Cornerstone home business will continue to be challenged given the aggressive promotional environment and expects uncertainty about the business to pressure the multiple.
09/20/16
09/20/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Ford (F) initiated with a Buy at Nomura. 2. Intel (INTC) was initiated with a Positive at Susquehanna while the firm initiated AMD (AMD) with a Neutral. 3. HSN, Inc. (HSNI) initiated with an Underperform at BofA/Merrill. 4. Bojangles (BOJA) initiated with a Strong Buy at CL King. 5. D.R. Horton (DHI) initiated with an Outperform at Wedbush. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/06/16
SBSH
10/06/16
DOWNGRADE
Target $43
SBSH
Neutral
HSN, Inc. downgraded to Neutral from Buy at Citi
Citi analyst Jason Bazinet downgraded HSN, Inc. (HSNI) to Neutral saying the company's business has been "slowly deteriorating." Unlikely Liberty Interactive (QVCA), HSN has not been using credit "to paper over" the underlying top-line deterioration, Bazinet tells investors in a research note. He now believes HSN shares may only reach $43 in 2018, suggesting less than 10% upside. The analyst lowered his price target for the shares to $43 from $53. Bazinet keeps a Buy rating on Liberty Interactive but lowered his price target for the shares to $26 from $33.

TODAY'S FREE FLY STORIES

03:00
06/23/17
06/23
03:00
06/23/17
03:00
General news
FX Update: The dollar has traded mostly softer »

FX Update: The dollar…

BMS

Bemis

$44.90

-0.28 (-0.62%)

20:30
06/22/17
06/22
20:30
06/22/17
20:30
Upgrade
Bemis rating change at BMO Capital »

Bemis upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATUS

Altice USA

20:29
06/22/17
06/22
20:29
06/22/17
20:29
Initiation
Altice USA initiated at Pivotal Research »

Altice USA initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

BBRY

BlackBerry

$11.06

0.41 (3.85%)

, FINL

Finish Line

$12.73

0.23 (1.84%)

20:25
06/22/17
06/22
20:25
06/22/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

BBRY

BlackBerry

$11.06

0.41 (3.85%)

FINL

Finish Line

$12.73

0.23 (1.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 23

    Jun

NBRV

Nabriva Therapeutics

$10.50

1.19 (12.78%)

20:22
06/22/17
06/22
20:22
06/22/17
20:22
Initiation
Nabriva Therapeutics initiated at Cantor »

Nabriva Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jul

WIX

Wix.com

$72.80

0.5 (0.69%)

20:20
06/22/17
06/22
20:20
06/22/17
20:20
Initiation
Wix.com initiated at Wedbush »

Wix.com initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

OCLR

Oclaro

$9.44

-0.1 (-1.05%)

20:19
06/22/17
06/22
20:19
06/22/17
20:19
Initiation
Oclaro initiated at DA Davidson »

Oclaro initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 26

    Jun

ACIA

Acacia Communications

$41.64

0.65 (1.59%)

20:19
06/22/17
06/22
20:19
06/22/17
20:19
Initiation
Acacia Communications initiated at DA Davidson »

Acacia Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 26

    Jun

LITE

Lumentum

$62.45

-0.05 (-0.08%)

20:19
06/22/17
06/22
20:19
06/22/17
20:19
Initiation
Lumentum initiated at DA Davidson »

Lumentum initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 26

    Jun

LEJU

Leju

$2.46

0.07 (2.93%)

20:05
06/22/17
06/22
20:05
06/22/17
20:05
Downgrade
Leju rating change at JPMorgan »

Leju downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GCP

GCP Applied Technologies

$30.40

0.3 (1.00%)

20:04
06/22/17
06/22
20:04
06/22/17
20:04
Upgrade
GCP Applied Technologies rating change at KeyBanc »

GCP Applied Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PHM

PulteGroup

$24.04

-0.24 (-0.99%)

19:58
06/22/17
06/22
19:58
06/22/17
19:58
Initiation
PulteGroup initiated at Credit Suisse »

PulteGroup initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DHI

D.R. Horton

$33.47

-0.5 (-1.47%)

19:58
06/22/17
06/22
19:58
06/22/17
19:58
Initiation
D.R. Horton initiated at Credit Suisse »

D.R. Horton initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAA

CalAtlantic

$34.80

-0.34 (-0.97%)

19:57
06/22/17
06/22
19:57
06/22/17
19:57
Initiation
CalAtlantic initiated at Credit Suisse »

CalAtlantic initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BZH

Beazer Homes

$13.01

0.03 (0.23%)

19:57
06/22/17
06/22
19:57
06/22/17
19:57
Initiation
Beazer Homes initiated at Credit Suisse »

Beazer Homes initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTH

Meritage Homes

$40.40

-0.4 (-0.98%)

19:57
06/22/17
06/22
19:57
06/22/17
19:57
Initiation
Meritage Homes initiated at Credit Suisse »

Meritage Homes initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TOL

Toll Brothers

19:57
06/22/17
06/22
19:57
06/22/17
19:57
Initiation
Toll Brothers initiated at Credit Suisse »

Toll Brothers initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LEN

Lennar

$52.41

-0.84 (-1.58%)

19:57
06/22/17
06/22
19:57
06/22/17
19:57
Initiation
Lennar initiated at Credit Suisse »

Lennar initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KBH

KB Home

$22.23

-0.1 (-0.45%)

19:57
06/22/17
06/22
19:57
06/22/17
19:57
Initiation
KB Home initiated at Credit Suisse »

KB Home initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

MHK

Mohawk

$242.70

-0.22 (-0.09%)

19:27
06/22/17
06/22
19:27
06/22/17
19:27
Initiation
Mohawk initiated at Credit Suisse »

Mohawk initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FBHS

Fortune Brands

$65.09

0.06 (0.09%)

19:27
06/22/17
06/22
19:27
06/22/17
19:27
Initiation
Fortune Brands initiated at Credit Suisse »

Fortune Brands initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JELD

JELD-WEN Holding

$34.60

-0.29 (-0.83%)

19:26
06/22/17
06/22
19:26
06/22/17
19:26
Initiation
JELD-WEN Holding initiated at Credit Suisse »

JELD-WEN Holding…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBP

Installed Building Products

$52.75

-1 (-1.86%)

19:26
06/22/17
06/22
19:26
06/22/17
19:26
Initiation
Installed Building Products initiated at Credit Suisse »

Installed Building…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OC

Owens Corning

$66.42

-0.85 (-1.26%)

19:26
06/22/17
06/22
19:26
06/22/17
19:26
Initiation
Owens Corning initiated at Credit Suisse »

Owens Corning initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WHR

Whirlpool

$195.16

1.35 (0.70%)

19:26
06/22/17
06/22
19:26
06/22/17
19:26
Initiation
Whirlpool initiated at Credit Suisse »

Whirlpool initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.